scispace - formally typeset
H

Hongmin Li

Researcher at New York State Department of Health

Publications -  102
Citations -  5468

Hongmin Li is an academic researcher from New York State Department of Health. The author has contributed to research in topics: T-cell receptor & Major histocompatibility complex. The author has an hindex of 36, co-authored 94 publications receiving 4738 citations. Previous affiliations of Hongmin Li include University of Arizona & University at Albany, SUNY.

Papers
More filters
Journal ArticleDOI

Structure and function of flavivirus NS5 methyltransferase.

TL;DR: The results demonstrate that the N-7 methylation activity is essential for the WNV life cycle and, thus, methyltransferase represents a novel target for flavivirus therapy.
Journal ArticleDOI

West Nile Virus 5′-Cap Structure Is Formed by Sequential Guanine N-7 and Ribose 2′-O Methylations by Nonstructural Protein 5

TL;DR: A critical role for the flavivirus MTase in viral reproduction is demonstrated and this domain is underscore this domain as a potential target for antiviral therapy.
Journal ArticleDOI

The structural basis of T cell activation by superantigens.

TL;DR: In this paper, the three-dimensional structure of bacterial superantigens and their complexes with MHC class II molecules and the TCRfl chain was studied. And the crystal structures also provided insights into the basis for the specificity of different SAGs for particular TCR fl chains, and for the observed influence of TCRfi chain on SAG reactivity.
Journal ArticleDOI

Crystal structure of a T-cell receptor β-chain complexed with a superantigen

TL;DR: The crystal structures of the β-chain of a TCR complexed with the Staphylococcus aureus enterotoxins C2 and C3 (SEC2, SEC3) are reported, revealing that the SAg acts as a wedge between the T CR and MHC to displace the antigenic peptide away from the TCR combining site.
Journal ArticleDOI

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

TL;DR: A brief review of the broad antiviral activity of niclosamide is summarized and its potential clinical use in the treatment of COVID-19 is highlighted.